Therapeutic Asset Ratings
395 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
[²¹²pb]pb-advc001
Prostate Cancer
AdvanCell Pty Limited
P1/2
CC
(40)
64cu-grip b
Prostate Cancer
Rahul Aggarwal
P1/2
CC
(40)
aaa602
Prostate Cancer
Novartis Pharmaceuticals
P1/2
CC
(40)
aaa802
Prostate Cancer
Novartis Pharmaceuticals
P1/2
CC
(40)
Ace-86225106
Prostate Cancer
Acerand Therapeutics (Shanghai) Limited
P1/2
CC
(40)
Actinium Rhpsma-10.1
Prostate Cancer
University College, London
P1/2
CC
(40)
Allogeneic Adipose-Derived Mesenchymal Stem Cells
Prostate Cancer
The Methodist Hospital Research Institute
P1/2
CC
(40)
AMXI-5001
Prostate Cancer
AtlasMedx, Incorporated
P1/2
CC
(40)
Apl-5125
Prostate Cancer
Apollo Therapeutics Ltd
P1/2
CC
(40)
as1986ns
Prostate Cancer
Antelope Surgical Solutions, Inc
P1/2
CC
(40)
azd9750
Prostate Cancer
AstraZeneca
P1/2
CC
(40)
BMS 986253
Prostate Cancer
Mark Stein
P1/2
CC
(40)
Camizestrant
Prostate Cancer
AstraZeneca
P1/2
CC
(40)
Chadox1-Pcaq
Prostate Cancer
Barinthus Biotherapeutics
P1/2
CC
(40)
coq10
Prostate Cancer
University of Nebraska
P1/2
CC
(40)
Datopotamab Deruxtecan
Prostate Cancer
AstraZeneca
P1/2
CC
(40)
Envafolimab
Prostate Cancer
Tianjin Medical University Second Hospital
P1/2
CC
(40)
Etx-19477
Prostate Cancer
858 Therapeutics, Inc.
P1/2
CC
(40)
Fianlimab
Prostate Cancer
University of Wisconsin, Madison
P1/2
CC
(40)
Fog-001
Prostate Cancer
Parabilis Medicines, Inc.
P1/2
CC
(40)
for46
Prostate Cancer
Rahul Aggarwal
P1/2
CC
(40)
Fractionated Dose Of 225Ac-J591
Prostate Cancer
Weill Medical College of Cornell University
P1/2
CC
(40)
ga-68-ngul
Prostate Cancer
Cellbion Co., Ltd.
P1/2
CC
(40)
her2 fpbmc
Prostate Cancer
University of Virginia
P1/2
CC
(40)
Hrs-1167
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1/2
CC
(40)
Showing 226 to 250 of 395 assets
Previous
Page 10 of 16
Next